Click it and Unblock the Notifications
Latest Updates
-
Who Is Charulatha Remesh? Sanju Samson’s ‘Dear Pondatti’ Post After India’s T20 World Cup Victory Wins Hearts -
Sheetala Saptami 2026: Significance, Vrat Katha And Why Families Eat Cold Food And Avoid Cooking This Day -
Suryakumar Yadav Takes T20 World Cup Trophy To 526 Year Old Adalaj Stepwell -
Horoscope for Today March 10, 2026 - Calm Energy, Steady Progress -
Women Car Rally Held In Gurugram On International Women’s Day, Boldsky Collaborates As Media Partner -
The Protein Gap In Women’s Diets: Gynaecologist Explains Why This Nutrient Matters From Puberty To Menopause -
Ralph Lauren Showcases ‘Jhumkas’ At Paris Fashion Week, Rekindling Debate On Credit For Indian Craft -
Viral Video: Pakistani Family Celebrates India’s T20 World Cup Victory With Cake, Sings Indian National Anthem -
Who Is Aditi Hundia? Viral Video Shows Ishan Kishan Celebrating India’s T20 World Cup Win With Girlfriend -
India Seal Historic T20 World Cup Win: Samson Tournament Star, Bumrah Match Hero, Dhoni Posts Special Message
New Therapy To Treat Inoperable Melanoma
A study at University of Pittsburgh Cancer Institute (UPCI) has cited that the combination of two different biotherapies may turn out to be more beneficial for patients with inoperable melanoma.
The researchers used two biotherapies, treatments that stimulate the immune system to fight cancer, and found that the results were quite promising in terms of anti-tumor effects and tolerable in terms of toxicity.
It was the first time that the researchers combined two biotherapies in this phase 2 trial. The biotherapies were: High-dose interferon alfa-2b, a standard treatment for metastatic skin cancer, and tremelimumab, an antibody thought to instigate the body"s immune system.
“With each new study, we learn something important about melanoma. With this study, we learned that adding tremelimumab to traditional treatment is not only safe, but an effective way to induce an anti-tumor response, which is very exciting," said John M. Kirkwood, M.D., leader of the program and professor and vice chairman for clinical research in the Department of Medicine, University of Pittsburgh School of Medicine.
In the study, the combination treatment was given to 16 patients diagnosed with stage 4 melanoma, all of whom received and had not benefited from at least one round of previous therapy
It was found that the overall response rate was 19 percent, and after that the study entered the second stage, where it will enroll 21 patients more.
Melanoma is a rare form of skin cancer, causing the majority of skin cancer-related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide, and currently surgery is the only effective cure.
In case of patients with inoperable disease, like those enrolled in this study, such discovery of a safe and effective treatment holds a big importance.
The study was presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.
Continue with Google